How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Texte intégral
Documents relatifs
When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring C Tron, F Lemaitre, Emeric Boisteau, S Le
Therapeutic efficacy of 5-fluorouracil-loaded poly( d , l -lactide-co-glycolide) microspheres (MS) was previously observed on C6 glioma-bearing rats (Menei et al., 1996; Lemaire et
A holistic approach to tackling the problems of food insecurity must, in effect, pursue simultaneously three goals namely: a substantial increase in the growth rate of food
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorec- tal cancer: results of a
In this paper, we will review further the clinical useful- ness and feasibility of HD-BU dose adjustment and patients' compliance monitoring through the determi- nation
The objectives that have been proclaimed many times have never been achieved, the best known being the commitment of states to devote 15 per cent of their national
Ainsi, dans le but d’apprécier le concept de la RSE d’une manière plus large et multiforme au regard du droit fiscal, Davis (1973) l’a défini comme une sorte de « prise en
Conclusion: In Belgium, we recommend phenotype or targeted genotype testing for DPD deficiency before starting 5-FU, capecitabine or tegafur.. We strongly suggest